Expected timeline: NDA filing Q4 2026, FDA review in 2027, possible approval late 2027, market launch 2028
Do not attempt this transition without direct clinical supervision
Alternatively, your doctor may suggest other weight loss treatments if you have not lost at least 5% of your starting weight
Although a drug is not illegal because it has side effects, this does not mean that a manufacturer may not be liable for having to pay for damages caused by the drug
To date, safety data on GLP-1 RAs in BC patients remain sparse
A recent study reported that dapagliflozin significantly downregulated the key markers of myocardial fibrosis, nitro-oxidative stress, pro-inflammatory cytokines, myocardial hypertrophy, fibrosis, and reduced apoptosis, ultimately retarding the development of HFpEF in diabetic rats [63]